Pharma BD Deal Intelligence
A $28.6 million bust: Antigenics bought Aronex for its liposomal oncology pipeline including Atragen for acute promyelocytic leukemia, but the FDA declined to approve Atragen and the acquired programs were later impaired as Antigenics refocused on Oncophage.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Antigenics will acquire Aronex Pharmaceuticals, gaining a product pipeline containing six late-stage drugs including Atragen for acute promyelocytic leukemia.
FDA declined to approve Atragen, stating Aronex's data did not establish an identifiable population of APL patients who need tretinoin and cannot use the oral…
Antigenics' 10-K disclosed acquired Aronex assets including Atragen, Annamycin, and Nyotran; subsequent filings reflect impairment and discontinuation of…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Antigenics acquired Aronex Pharmaceuticals for approximately $28.6 million, adding liposomal oncology assets (Atragen for acute promyelocytic leukemia, Annamycin, and Nyotran) to its heat-shock-protein-based cancer-vaccine platform. The Aronex programs were subsequently impaired or discontinued as Antigenics refocused on its lead candidate Oncophage.
2K US cases/yr
Acute promyelocytic leukemia (APL) is an aggressive subtype of acute myeloid leukemia driven by the PML-RARA fusion oncogene from the t(15;17) translocation. Without treatment, APL is rapidly fatal due to coagulopathy and bleeding; with all-trans retinoic acid (ATRA) plus arsenic trioxide, it is now the most curable AML subtype, achieving ~80-90% long-term survival. APL accounts for ~1,500 annual US cases.
At the time of the July 2001 Antigenics-Aronex acquisition, the APL standard of care was Roche's oral Vesanoid (tretinoin / all-trans retinoic acid) capsules combined with anthracycline chemotherapy; Cell Therapeutics/Cephalon's Trisenox (arsenic trioxide) had just received FDA approval (Sept 2000) for relapsed/refractory APL. Aronex's Atragen was a liposomal IV tretinoin formulation positioned for patients unable to take oral therapy — pediatric, intubated, or vomiting induction patients — producing plasma concentrations >10x higher than oral capsules (per ASH Blood publication and pharmaceuticalonline.com). Antigenics inherited Atragen plus Annamycin (liposomal anthracycline for breast cancer / refractory leukemia) and Nyotran (liposomal nystatin for systemic fungal infections). The strategic logic combined Aronex's late-stage liposomal oncology assets with Antigenics' Oncophage HSP-based cancer vaccine platform. The deal underperformed: FDA issued repeat non-approvable letters for Atragen citing inadequate identification of an oral-failure population (per Pharmaletter coverage), and Antigenics later wrote down the Aronex assets, eventually pivoting fully to immuno-oncology as Agenus. Source: https://www.thepharmaletter.com/antigenics-to-acquire-aronex-pharmaceuticals
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Antigenics Inc. / Aronex Pharmaceuticals Inc. (this deal) | 2001 | $29M | — |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Barr Laboratories Inc. / Duramed Pharmaceuticals Inc. | 2001 | $589M | 82 |
| Cephalon Inc. / Group Lafon (France) | 2001 | $450M | 80 |
← Browse all deals · How we score deals
More: 2001 deals